Bridgewater Chapter Upcoming Events Join PCCI

Requis Pharma Inc.

A new product development company

Presenter: Lars Knutsen, President and CEO of Requis


Monday, March 11, 2013

Embassy Suites, Chesterbrook, Pennsylvania (directions)




Business Summary: Requis Pharma Inc. is a new Product Development company, founded by experienced entrepreneurs in West Chester, PA. Strategy is to bring patented products to revenue generation rapidly by targeting the US OTC market; a series of global Rx drugs will follow. Requisom is a novel sleep-aid, and Cirrus a new beverage for Jet-Lag Disorder. Requis will develop and license drugs to major US companies for marketing; US OTC sleep-aid market is >$750 M p.a.


Product/Services: Requisom, a patented OTC sleep-aid for the US market, is our most advanced product. It comprises a new combination of approved ingredients, targeting those experiencing occasional sleep problems, i.e. difficulty falling asleep or maintaining sleep. Requisom comprises a lowered dose of a sedating antihistamine as the API, with 2 dietary supplements that improve sleep. The company has also developed a beverage, Cirrus, for treatment of Jet Lag.


Customer problem: Estimates show that 50-70M Americans are unable to get a good night's sleep due to worries: the economy, keeping their jobs, or their money, according to a recent National Sleep Foundation poll. Add to those increasing numbers of people over age 60 who have a harder time falling asleep and wake more often than average. There is a sub-group of those with sleeplessness, travelers suffering from Jet Lag, who are also a market for Requis Pharma.


Target market: The initial target market for Requisom, the company’s first Pharma product, is the 50 - 70M Americans suffering from occasional sleeplessness. Analyses of trends in society show that sleep disorders are on the rise. This drug will be Rx in Europe. Cirrus, the functional beverage for treatment of Jet Lag Disorder will be launched into the very new US relaxation drinks market; > 20M people per year travel across 2+ time zones per year.



3 Major Issues


  1. Is there a sufficiently strong unmet medical need within the treatment of occasional sleeplessness (Requsiom) and Jet Lag Disorder (our Cirrus beverage) to attract investment for development of Requis Pharmaceuticals' initial products?

  2. Should we look to out-license and divest Cirrus or plan outsourced manufacture, distribution and marketing ourselves?

  3. Licensing strategy: Does PCCI suggest an early or later approach to companies which may be potential licensees of Requisom? Vicks have recently launched ZzzQuil, which represents no advance over existing products, since it is just diphenhydramine.




6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)

8:00 - Lars Knutsen, President and CEO of Requis, will deliver the Company's "Elevator" Pitch to the Group

8:20 - A Panel will address 3 Major Issues for the Company

9:00 - Open discussion: members and guests



<Top of the page>




Available Media

Please note: All information obtained here is the property of those presenting and should not be copied or duplicated without written consent.



None available at this time


None available at this time


None available at this time


Requis Pharma Webcast - 03/11/13

Contact Info:




Our Sponsors


EisnerAmperIdeas x Innovation Network i2nNew Jersey Institute of TechnologyScience Center


<Top of the page>






Questions or Coments?

Contact: Peter van der Kam, | (610) 296-8086




Good Company! Good Drink! Good Food! Good Program! Good Fun!


Site Navigation



Pharmaceutical Consulting Consortium International, Inc., or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2018



Tat Communication Inc